Life Sciences Archives - Page 2 of 20 - Becker's Hospital Review

Novo says Wegovy pill beats Lilly's orforglipron | Trump bought Eli Lilly stock during coverage push | Melanoma drug rejected again | Generic Ozempic could be delayed | FDA approves 1st-in-class blood pressure drug

Novo vs. Lilly, Trump’s stock trade, a melanoma setback and an Ozempic delay. May 20, 2026 1. Novo says Wegovy pill trumps Lilly’s orforglipron in key measures Full story 2. FDA rejects melanoma drug, again Full story 3. How WakeMed,…

GLP-1s linked to higher breast cancer survival | Mounjaro dethrones Keytruda as world's top-selling drug | The peptide craziness hits US | Pancreatic cancer drug extends survival 8 months | 7 new drugs in shortage

Mounjaro dethrones Keytruda and GLP-1s may help cancer patients live longer. May 13, 2026 1. GLP-1s linked to higher breast cancer survival: 3 notes Full story 2. Mounjaro surpasses Keytruda as top-selling drug Full story 3. Revenue leakage starts before…

The next GLP-1 boom | Mark Cuban's 8-part healthcare playbook | New Alzheimer's treatment approved | FDA approves 1st gene therapy for hearing loss | US drug shortages on the rise

GLP-1 and gene therapy breakthroughs, plus a drug shortage warning. May 6, 2026 1. The next phase of the GLP-1 boom Full story 2. FDA approves new Alzheimer's agitation treatment Full story 3. Advocate Health, Mayo Clinic and 515+ speakers…

Pancreatic cancer pill shows promise | 130+ groups warn on CDC vaccine changes | FDA approves 1st 2-drug HIV treatment | AI life sciences research model debuts | CEOs push back on lawmakers on hospital profits

Cancer drug progress, CDC vaccine concerns, HIV approval and a new AI model. April 29, 2026 1. Pancreatic cancer pill, vaccine show promise: What to know Full story 2. FDA approves 1st 2-drug HIV treatment Full story 3. Healthcare's technology…

Xanax recalled over quality issue | 4 things to know on ibogaine | FDA seeks safety data on new Eli Lilly GLP-1 | 6 new drugs in shortage | 5 FDA moves shaping drug development

FDA oversight updates, new GLP-1 studies and a drugmaker recall. April 22, 2026 1. Drugmaker recalls Xanax over quality issue Full story 2. FDA seeks additional safety data for Lilly GLP-1 pill Full story 3. AI governance, RCM, interoperability —…

Genes may predict GLP-1 success | FDA OKs 1st Farxiga generics | GLP-1s shift care patterns: 4 notes | FDA adds seizure warning to flu vaccine label | Hemophilia gene therapy access halted

New GLP-1 trends, FDA approvals and emerging safety concerns. April 15, 2026 1. Genes may predict GLP-1 weight loss: Study Full story 2. FDA approves 1st generics of Farxiga for Type 2 diabetes Full story 3. Advocate Health, Mayo Clinic…

FDA seeks sweeping budget changes | 200+ active drug shortages persist | Eli Lilly's GLP-1 pill wins FDA nod | COVID study halted | 3.1M eye drops recalled

FDA budget overhaul, 200+ drug shortages and new GLP-1 updates. April 8, 2026 1. FDA seeks sweeping policy changes in budget proposal Full story 2. 216 active drug shortages: How 1 health system is managing Full story 3. Reviewer badge…

Amgen drug faces FDA scrutiny after 8 deaths | FDA OKs 1st weekly basal insulin | Drug supplies at risk amid Iran war | FTC, CVS near antitrust settlement | 13 potential GLP-1 benefits

FDA actions, drug risks and GLP-1 upside: 6 Life Sciences updates April 1, 2026 1. Amgen drug under FDA review in wake of 8 deaths Full story 2. The medications most at risk amid Iran war-driven supply threats Full story…

Stopping GLP-1s tied to 22% rise in heart attacks | Pfizer's Lyme vaccine heads to FDA | Eli Lilly's new GLP-1 cuts weight, A1C | Novel hemophilia gene therapy debuts in Detroit | FDA recalls 89K ibuprofen bottles

GLP-1 risks, a Lyme vaccine, gene therapy debut and an ibuprofen recall in focus. March 25, 2026 1. Stopping GLP-1s linked to 22% rise in heart attack: 5 study notes Full story 2. Pfizer Lyme vaccine candidate heads to FDA…

HHS eyes $200M cancer vaccine push | Senate probes FDA drug denials | Novo missed adverse event reports | Demand grows for unproven autism drug | 3 GLP-1 updates

HHS eyes $200M cancer vaccine effort as FDA faces Senate probe. March 18, 2026 1. HHS plans $200M cancer vaccine initiative: Wall Street Journal Full story 2. Clinicians divided amid growing demand for unproven autism drug Full story 3. Reviewer…